Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Earnings for Agios Pharmaceuticals, Inc. (AGIO)
Earnings in 2023 (TTM): $-352,088,000
According to Agios Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-352,088,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Agios Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-352,088,000 | $-352,088,000 |
| 2022 | $-231,801,000 | $-74,555,000 |
| 2021 | $-356,510,000 | $1.6 B |
| 2020 | $-327,370,000 | $-335,218,000 |
| 2019 | $-411,472,000 | $-396,611,000 |
| 2018 | $-346,028,000 | $-346,028,000 |
| 2017 | $-314,670,000 | $-314,670,000 |
| 2016 | $-198,471,000 | $-198,471,000 |
| 2015 | $-117,732,000 | $-117,732,000 |
| 2014 | $-53,930,000 | $-53,504,000 |
| 2013 | $-38,828,000 | $-39,407,000 |
| 2012 | $-22,926,000 | $-20,102,000 |
| 2011 | $-16,499,000 | $-23,706,000 |